All In Biotech

Drug Trial Radar · NCT07578337

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

A Randomized Phase II Study of Priming Treatment With the Hedgehog Inhibitor NLM-001 Prior to Gemcitabine/Nab-Paclitaxel (GNab-P) plusBotensilimab and Balstilimab (Bot/Bal) Versus GNab-P in Patients With Previously Untreated Advanced Pancreatic Cancer (NUMANTIA-2)

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Feb 28, 2029

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Nelum CorpIndustry
Sponsor type
Industry
Collaborators
Apices Soluciones S.L.; PH Research, S.L.
First posted
May 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unacceptable toxicity. In the experimental arm, patients who discontinue chemotherapy for reasons other than disease progression may continue receiving the remaining study drugs (NLM-001, botensilimab and balstilimab) up to a maximum of 24 months, according to schedule.

Conditions

  • Untreated
  • Advanced Pancreatic Cancer

Interventions

  • Gemcitabine (1000 mg/m2)Drug

    Gemcitabine 1,000 mg / m2 IV administered on days 1, 8 and 15 in cycles of 28 days.

  • Nab-paclitaxel (Abraxane)Drug

    Nab-P 125 mg / m2 IV administered on days 1, 8 and 15 in cycles of 28 days.

  • NLM-001Drug

    NLM-001: 800 mg/day, p.o, once daily (4 tablets of 200 mg) days -4 to -1 and 10-13 of each cycle.

  • BotensilimabDrug

    Botensilimab: 75 mg every 6 weeks for 4 administrations, from D1C1.

  • BalstililmabDrug

    Balstilimab: 240 mg IV Day 1 and Day 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the response rate in each of the study arms, assessed according to iRECIST criteria, including the confirmation of progression to distinguish true progression from potential pseudoprogression.Time frame: 12 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, Spain

  • Hospital Clínic Barcelona

    Barcelona, Barcelona, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Universitario de Donostia

    San Sebastián, Gipuzkoa, Spain

  • Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, La Coruña, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.